Case report

Pelvic Lymphadenectomy in Prostate Cancer Treatment

Ante Reljić
Danijel Justinić
Goran Štimac
Borislav Spajić
Ognjen Kraus

Abstract

Despite the increasing number of patients being detected with a clinically localized (T1,2) prostate cancer, pelvic lymphadenectomy remains a standard in determining the exact histological staging as a reliable prognostic parameter. Extended lymphadenectomy is superior to limited lymphadenectomy, and with the use of appropriate surgical technique does not contribute significantly to the operative morbidity while providing an evidence based indication for additional treatment modalities. Lymphadenectomy may not be indicated in patients at a low risk of regional lymphatic metastasis (impalpable T1 carcinoma, PSA less than 10 and Gleason score less than 6), depending on the preferences of the surgeon and the patient. In all other patients, it is reasonable to perform lymphadenectomy, at least a limited one, however, extennded lymphadenectomy is being increasingly recommended. Good cooperation with clinical pathologist is of great importance. Pelvic lymphadenectomy is most probably without an oncologic therapeutic effect in highly selected patients with favorable prognostic factors. Although data concerning therapeutic effect of extended lymphadenectomy are few and contradictory, there are convincing indications of the possible therapeutic effect of such an approach, in particular for patients with micrometastases.

Keywords

Prostatectomy – methods; Prostatic neoplasms – surgery; Prostatic neoplasms – pathology; Lymph node excision – methods

Hrčak ID:

12712

URI

https://hrcak.srce.hr/12712

Publication date:

30.3.2007.

Article data in other languages: croatian

Visits: 2.534 *